Introduction
Signal transducers and activator of transcription (STAT) are transcriptional regulators that play a central role in cytokine and growth factor signaling (for a review, see Kisseleva et al., 2002) . Upon stimulation with cytokines, receptor-associated Janus kinases (JAKs) phosphorylate STATs on a single tyrosine residue located in their carboxy-terminal region, an event that triggers STAT dimerization through the reciprocal intermolecular interactions between the phosphotyrosine residue of one STAT monomer with the Src homology 2 domain of another monomer. Dimerized STATs translocate to the nucleus where they bind to specific palindromic DNA elements (GAS motifs) as dimers or tetramers, depending upon the promoter context to regulate transcription of target genes.
Signal transducers and activator of transcription 5 is activated by a number of class I cytokines. Gene inactivation studies in mice have demonstrated a nonredundant role of STAT5A in prolactin signaling, leading to defective mammary gland development (Liu et al., 1997; Cui et al., 2004) and of STAT5B in growth hormone signaling, leading to growth retardation (Udy et al., 1997 ). An hypomorphic STAT5A and B loss of function mutant shows that these proteins also play a redundant role in the response of hematopoietic cells to a wide variety of cytokines and result in a dramatic decrease in stem-, multipotent and lineage-committed progenitors (Teglund et al., 1998; Bunting et al., 2002; Snow et al., 2002) . The study of this loss of function mutant mouse and of transgenic mice with lymphoidspecific targeting of STAT5A or B have identified critical roles of STAT5 in interleukin (IL)-7 receptor signaling in both fetal thymocyte and early B-cell progenitor development (Sexl et al., 2000; Burchill et al., 2003; Goetz et al., 2004 Goetz et al., , 2005 Kang et al., 2004) , in cytokine-induced proliferation of peripheralactivated T cells and memory T cells (Burchill et al., 2003; Kelly et al., 2003a; Moriggl et al., 1999) and in the development of CD4 þ CD25 þ regulatory T cells and natural killer-T cells (Burchill et al., 2003) .
Constitutive STAT5 tyrosine phosphorylation and DNA-binding activity are frequently observed in myeloid and lymphoid malignancies (for a review, see Benekli et al., 2003) and in carcinoma (for a review, see Bromberg, 2002) . In some instances, STAT5 activation has been directly linked to the activity of oncogenic protein tyrosine kinases, including BCR-ABL in chronic myeloid leukemia (CML), TEL-JAK2 in acute lymphoid leukemia (ALL) and CML and mutated FLT3 in about half of the cases of acute myeloid leukemia AML (Carlesso et al., 1996; Lacronique et al., 1997; Carron et al., 2000; Mizuki et al., 2000) . Signal transducers and activator of transcription 5 is also activated in response to constitutive JAK2 resulting from the V617F mutation observed in patients suffering from myeloproliferative disorders, in particular polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis (James et al., 2005; Levine et al., 2005) . In vitro studies and genetic approaches in mouse models of these diseases show that STAT5 activation is critical in some (Nieborowska-Skorska et al., 1999; Schwaller et al., 2000) but not all instance (Sexl et al., 2000) . The molecular basis for the persistent activation of STAT5 in most cases of AML and B-and T-cell ALL (Weber-Nordt et al., 1996) is however not determined, nor is its significance in either initiation, progression or maintenance of these leukemias.
Several experimental approaches have been used to analyse the intrinsic oncogenic activity of wild-type (wt) and mutant STAT5. Transgenic overexpression of wt STAT5A or STAT5B has been shown to result in T-cell leukemia, but leukemic cells do not present constitutive STAT5 tyrosine phosphorylation, suggesting deregulation of molecular pathways distinct from those involved in human leukemia displaying high, constitutive STAT5 tyrosine phosphorylation (Kelly et al., 2003b) . Point mutants of STAT5 displaying constitutive tyrosine phosphorylation and DNA binding have been generated through their ability to confer cytokine-independent survival and proliferation of the IL-3-dependent Ba/F3 cells (Onishi et al., 1998) . Overexpression of these mutants -but not wt STAT5 -in mouse bone marrow cells followed by adoptive transfer of transduced cells in irradiated syngeneic hosts resulted in either myelo-or lymphoproliferative disorders with a significant non-cell autonomous component (Schwaller et al., 2000) , or multilineage leukemia (Moriggl et al., 2005) .
In this study, we show that transgenic expression of a tetramerization-prone, constitutively activated STA-T5A(S711F) mutant at levels similar to endogenous STAT5 results in B-cell leukemia/lymphoma at low frequency and after long latency. The emergence of these leukemias is associated with the activation of additional pathways, as evidenced by their clonal nature and their association with further upregulation of STAT5 tyrosine phosphorylation. Finally, we show that STAT5A(S711F) strongly cooperates with the loss of function of the p53 tumor suppressor gene, resulting in the specific acceleration of B-cell lymphomagenesis.
Results

Generation of STAT5A(S711F) transgenic mice and developmental analyses
The cDNA encoding a C-terminal-flagged version of STAT5A(S711F) (Onishi et al., 1998) (referred to as STAT5A* thereafter) was inserted into the lymphoidspecific Em enhancer-based pEmSRa vector (Bodrug et al., 1994) (Figure 1a ). After microinjection of the EmSRa-STAT5A* transgene into blastocysts, seven founders were obtained. Transgenic lines were derived from all founders, but only three (founder lines 48, 41 and 24) displayed detectable expression of STAT5A* in lymphoid organs, as analysed by Western blot using an anti-Flag antibody (Figure 1b) . Mice from one of these lines (line 48) were backcrossed for over seven generations on C57BL/6 mice and followed for up to 2 years.
Comparison of the total level of STAT5A expression using a STAT5A-specific antibody between lymphoid tissues of transgenic STAT5A* (TgSTAT5A*) and littermate controls (LMC) showed that the transgeneencoded STAT5A* was expressed at levels similar to endogenous STAT5A. Indeed, iterative Western blot analyses showed that the total amount of STAT5A expressed in lymphoid tissues of TgSTAT5A* mice was similar to the levels observed in lymphoid organs of agematched LMC (Figure 1c , see also Figure 2c ). In line with the reported persistent tyrosine phosphorylation of STAT5A* seen in the absence of cytokines (Onishi et al., 1998) , enhanced STAT5 phosphorylation on tyrosine 694 was observed in the lymphoid tissues of TgSTA-T5A* mice as compared to LMC (Figure 1c , see also Figure 2c ).
Recent analyses of mice expressing a transgene encoding the constitutively active STAT5B(H299R/ S711F) mutant reported several alterations in lymphoid cell development and homeostasis (Burchill et al., 2003; Goetz et al., 2004) . Transgenic STAT5A* mice showed similar developmental defects, although with lower penetrance. Indeed, irrespective of their age, TgSTA-T5A* mice displayed enlarged spleen and lymph nodes, as compared to LMC. The two-fold increase in spleen cellularity resulted from multilineage amplification of myeloid and lymphoid cells as determined by fluorescence-activated cell sorter (FACS) analysis ( Figure S1 , supplementary data). Splenic CD8 þ T-cell numbers were slightly increased, including a two-fold enhancement in CD44 þ CD122 þ memory T cells (42% in TgSTAT5A* vs 22% in LMC), whereas the total number of CD4 þ T cells remained unaffected, thus resulting in a 30% increase in CD8/CD4 ratio (Table S1 , supplementary data). In the CD4 compartment, a twofold increase in CD4 þ CD25 þ T cells was observed, irrespective of the age of the animals (Table S1 , supplementary data). In bone marrow, B-cell development was also affected with a two-fold expansion in pro-B þ pre-B and immature B-cell progenitors and a decrease in mature B cells (data not shown).
Hypercellularity of peripheral lymphoid organs could result from a decrease in apoptosis or/and an increase in cell proliferation. In vitro apoptosis assays failed to reveal any significant difference between lymphoid cells of LMC and TgSTAT5A* mice. In addition, no difference in sensitivity towards apoptosis inducers including dexamethasone, cross-linked anti-CD3, phorbol 12-myristate 13-acetate (PMA) alone, PMA þ ionomycin and super Fas ligand was observed between TgSTAT5A* and LMC thymocytes (data not shown). In contrast, thymocytes and purified peripheral T cells of TgSTAT5A* mice showed enhanced sensitivity to mitogenic stimuli as compared to their LMC counterparts. Although the proliferative response of TgSTAT5A* and LMC peripheral T cells to low concentrations of anti-CD3 was similar, TgSTAT5A* T cells showed enhanced sensitivity to IL-2 stimulation 
STAT5A* induces B-cell lymphoma in aged animals
Aged TgSTAT5A* mice displayed several pathological abnormalities in particular tumor development. These abnormalities typically arose between 9 and 22 months of age in the cohort of 50 mice analysed. A group of five mice became moribund and shared a similar pathology characterized by systematic enlargement of the thymus, massive splenomegaly and lymphadenopathy and high white blood cell counts, whereas another mouse (no. 1043) displayed splenomegaly with the accumulation of peritoneal liquid (Table S2 , supplementary data). The thymus, spleen and lymph nodes cells of diseased mice were analysed by cytometry for the expression of T-, B-, granulomonocytic-and erythroid lineage-specific markers. As shown in Table 1 , all affected organs and the peritoneal liquid of mouse no. 1043 showed massive invasion by cells belonging to the B-cell lineage, with B cells representing up to 90% of thymic, splenic and lymph node cell populations. These B-cell-lineage expansions were clonal/oligoclonal as demonstrated by the presence of discrete rearranged alleles of the immunoglobulin (Ig)H locus as assessed by Southern blot analyses, using an IgH JH4-specific probe ( Figure 2a) . The leukemic cells of mouse no. 15 phenotypically resembled immature and mature B cells (Table 1 ). In contrast, the leukemic cells of the other animals were clearly abnormal, being characterized by low CD45 cell surface expression as assessed by B220-and CD45-specific antibodies ( Figure 2b and Table 1 ) and the expression of B-cell-lineage markers not normally co-expressed during normal B-cell development, suggesting an aberrant differentiation arrest at the pre B/immature B stages (Table 1 ). The abnormal B cells from mice no. 8 and no 17 were tested for transplantability following subcutaneous injection into nu/nu (Table 1) . We conclude from these observations that the activated STAT5A* mutant is oncogenic in the mouse lymphoid lineage, leading to the emergence of clonal B-cell lymphoma/ leukemia in about 10% of the animals after a long latency. STAT5A* cooperates with the loss of function of p53 in B-cell lymphomagenesis As B-cell lymphoma/leukemia was rarely observed in TgSTAT5A* mice and developed only late, we sought to increase tumor incidence by manipulating the genetic background of the host. Alterations in the p53 pathway are associated with disease progression and unfavorable outcome in human B-cell lymphoma and leukemia (for a review, see Krug et al., 2002) , whereas its disruption accelerates Myc-induced B-cell lymphomagenesis in mouse (Eischen et al., 1999; Schmitt et al., 1999; Hemann et al., 2003) . We therefore analysed whether STAT5A* could cooperate with the loss of the p53 STAT5 activation in B-cell neoplasia V Joliot et al tumor suppressor gene in B lymphomagenesis. Transgenic STAT5A* mice were crossed with BALB/c p53-deficient mice and F1 offsprings were backcrossed with p53À/À mice to generate four F2 cohorts, namely TgSTAT5A*/p53À/À, TgSTAT5A*/p53 þ /À, as well as p53À/À and p53 þ /À littermates that were followed over time for tumor development. In line with previous studies (Donehower et al., 1992; Jacks et al., 1994) , all p53À/À mice developed a large spectrum of tumors, including T-cell, B-cell, mixed lymphoid, lymphoid/ erythroid or erythroid leukemia as well as solid tumors, whereas p53 þ /À heterozygotes remained tumor-free for over a year (Figure 3a and b) . The combination of the STAT5A* transgene with either the p53À/À or p53 þ /À mutations clearly accelerated the time course of tumor development as compared to the respective littermates (Figure 3b ). The mean age for tumor development was 11 weeks for TgSTAT5A*/p53À/À mice and 18 weeks for p53À/À littermates, a statistically significant difference (Po0.0001). In the p53 þ /À genetic background, the STAT5A* transgene also accelerated disease (mean age of tumor development: 40 weeks) as compared to non-transgenic p53 þ /À mice (Po0.0001) (Figure 3b) . The TgSTAT5A*/p53À/À mice also clearly differed from their p53À/À littermates with respect to the type of hematological disorders they developed. All TgSTAT5A*/p53À/À mice were affected by a disease characterized by high white blood cell counts, splenomegaly, adenopathy and for some, an enlarged thymus. Lineage marker analyses showed that 
STAT5 activation in B-cell neoplasia
V Joliot et al the majority of TgSTAT5A*/p53À/À and close to 90% of TgSTAT5A*/p53 þ /À lymphoma/leukemia were of B-cell origin (Figure 3a and c) . These lymphoma/ leukemia were clonal or oligoclonal diseases as shown by analysis of the rearrangement of the IgH chain gene locus (Figure 4a ). Three TgSTAT5A*/p53À/À mice developed a mixed B and T lymphoma characterized by the co-expansion in the thymus of clonal leukemic T and B cells as evidenced by specific rearrangements in both the TCRb and the IgH locus (Figure 3a and c; data not shown). Occasional TgSTAT5A*/p53À/À and TgSTA-T5A*/p53 þ /À animals displayed a multilineage pathology (Figure 3a and c) . We conclude from these results that STAT5A* specifically cooperates with the inactivation of the p53 pathway in B-cell lymphomagenesis. As transgenic STAT5A*/p53 þ /À mice developed lymphoma after longer latency than TgSTAT5A*/ p53À/À mice, we analysed the status of p53 in the former. Loss of the p53 wt allele appears to occur during disease progression in STAT5A*/p53 þ /À mice as the relative representation of the knockout vs wt p53 allele in leukemic organs increased in relation to the degree of Figure 4 Signal transducers and activator of transcription (STAT)5 phosphorylation and activation in transgenic STAT5A* (TgSTAT5A*)/p53 þ /À leukemias. (a) Southern blot analysis of genomic DNA from leukemic cells obtained from the invaded spleen of the TgSTAT5A*/p53 þ /À mice no. 1092, from the invaded lymph nodes of the TgSTAT5A*/p53À/À mice no. 1157 and from the invaded spleen of p53À/À mice no. 1143. DNA obtained from spleen cells of non leukemic mice TgSTAT5A* no. 1075 was used as control. Genomic DNA was digested with EcoRI and the rearrangement of the IgH locus analysed by hybridization with a specific IgH-JH4 probe. The arrow indicates the germline configuration and the stars point to the distinct IgH locus clonal rearrangement observed in STAT5A*-induced lymphoma/leukemia. (b) Cellular extracts from lymph nodes cells obtained from B-cell lymphoma/ leukemia that arose in TgSTAT5A*/p53 þ /À and TgSTAT5A*/p53À/À mice and spleen cells from the non-leukemic no. 1102 mice were analysed on Western blot with anti-phospho-STAT5, anti-Flag and anti-STAT5 antibodies. Normalization was performed with an anti-extracellular signal-regulated protein kinase (ERK)2 antibody. (c) Electrophoretic mobility shift assays were carried out with the b-caseinX2 probe and nuclear extracts from thymocytes from LMC and a non-leukemic TgSTAT5A*/p53 þ / þ mouse and from a thymic tumor from a TgSTAT5A*/p53 þ /À mouse. An arrow indicates the STAT5/DNA complex. DNA-binding inhibition assays using either a STAT5-specific antibody or an irrelevant anti-NFAT antibody assessed specificity of this complex. Note that the anti-STAT5 antibody used does not supershift the complex but inhibits DNA binding of STAT5. (d) Specificity of the STAT5/DNA complex was further assessed by competition with a 200-fold excess of an unlabeled oligonucleotide corresponding to the classical b-casein promoter STAT5 element (wt) or a version of this oligonucleotide (mut) mutated in the STAT5 DNA-binding site core. Arrows indicate the specific STAT5/probe complex; arrowheads point to a non-specific complex, detected only in the absence of high STAT5 DNA binding.
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invasion of the affected organ by leukemic cells (data not shown). Cell lines could be established in vitro from TgSTAT5A*/p53À/À, TgSTAT5A*/p53 þ /À and p53À/À B-cell lymphoma, which self-renewed for >50 generations. Analysis of the status of the p53 allele in TgSTAT5A*/p53 þ /À leukemic cell lines revealed the systematic loss of the p53 wt allele (data not shown).
Similar to TgSTAT5A* lymphoma/leukemia, the accelerated disease in p53-deficient TgSTAT5A* mice was also associated with STAT5 hyperphosphorylation. A higher level of STAT5 tyrosine phosphorylation was detected in leukemic cells from TgSTAT5A*/p53 þ /À animals as compared to lymphoid tissues of nondiseased transgenic mice. The upregulation of STAT5 phosphorylation was also observed in 14 out of 16 TgSTAT5A*/p53À/À leukemias analysed (Figure 4b and data not shown). In contrast, none of the lymphoma observed in p53À/À mice displayed STAT5 phosphorylation (data not shown). Recent analyses have shown that STAT5A* leukemogenic properties are linked to its ability to bind DNA as a tetramer on specific DNA response elements (Moriggl et al., 2005) . We therefore analysed STAT5 DNA-binding activity in leukemic cells, and as control, lymphoid cells obtained from LMC and non-diseased TgSTAT5A* animals. Electrophoretic mobility shift assay was performed using a STAT5 tetramer-specific DNA probe. The results of Figure 4c show that nuclear extracts from TgSTAT5A* leukemic cells displayed enhanced STAT5 DNA-binding activity as compared to non-leukemic TgSTAT5A* and LMC lymphoid tissues. The STAT5/DNA complex is specific as its formation was inhibited by the inclusion in the binding reaction of a 200-fold molar excess of unlabeled STAT5-specific oligonucleotide used as competitor but not by the same oligonucleotide mutated in its STAT5 binding core (Figure 4d ). This complex corresponds to STAT5 binding to the probe as its formation was specifically inhibited by an anti-STAT5 antibody but not by a control antibody (Figure 4c ).
Upregulation of STAT5 phosphorylation in STAT5A*-induced lymphoma is dependent on Janus kinases activation To gain information on the nature of the signaling pathways involved in STAT5 activation, we analysed the effect of several protein tyrosine kinase inhibitors on STAT5 phosphorylation in primary cultures of TgSTA-T5A*/p53 þ /À tumors. As shown in Figure 5a , STAT5 phosphorylation was only marginally affected in the presence of PP1, an inhibitor of the SRC family of tyrosine kinase. In contrast, a pan-JAK inhibitor or AG490, a less specific JAK inhibitor, decreased STAT5 tyrosine phosphorylation in a dose-dependent manner (Figure 5a and data not shown). These results suggested that activation of a JAK-dependent pathway was involved in STAT5 hyperphosphorylation in TgSTA-T5A*-induced leukemia. As the IL-7-R/JAK/STAT5 pathway plays an essential role in normal B-cell development (Goetz et al., 2004) , we analysed the expression of IL-7R in TgSTAT5A* leukemias. Reverse transcriptase-polymerase chain reaction and FACS analyses showed that all TgSTAT5A* leukemia analysed expressed IL-7Ra at both the RNA and protein levels (Figure 5b and c) . These cells also responded to IL-7 stimulation by further increasing their level of STAT5 tyrosine phosphorylation, demonstrating the expression of a functional IL-7R (data not shown). Of note, a subset of TgSTAT5A* leukemias also upregulated the expression of IL-7 transcripts (Figure 5b) . STAT5 hyperphosphorylation could also result from impaired downregulation of JAK/STAT5 signaling in TgSTAT5A* leukemic cells. In line with our previous observations in TgSTAT5A* leukemias (Figure 2b ), TgSTAT5A*/p53À/À leukemias also displayed lower cell surface expression of the CD45 tyrosine phosphatase as compared to non genetically modified LMC as well as non-diseased p53À/À mice and TgSTAT5A*/ p53À/À (Figure 6a ). In contrast, we found no evidence for decreased expression of the SHPTP2 and PTP1B STAT5 tyrosine phosphatases in TgSTAT5A* leukemia as compared to control cells (Figure 6b) . Likewise, expression of other negative regulators of the JAK/ STAT pathway, including SOCS1 and SHPTP1 was found to be unaffected in TgSTAT5A* leukemic cells as compared to control cells (Figure 6b ).
Discussion
The STAT5A* mutant used in this study has previously been shown to display persistent tyrosine phosphorylation as compared to wt STAT5 (Onishi et al., 1998; Moriggl et al., 2005 ; our unpublished observations). Accordingly, lymphoid cells of non-diseased TgSTA-T5A* mice show enhanced tyrosine phosphorylation of STAT5, likely reflecting the enhanced sensitivity of the STAT5A* mutant to endogenous cytokine signaling. Recent studies using STAT5-deficient mice and transgenic mice engineered to either overexpress the constitutively active STAT5A(H299R;S711F) double mutant (Burchill et al., 2003) or wt STAT5 (Kelly et al., 2003a) have shown that STAT5 plays an important role in IL-7-mediated pro-B-cell survival and proliferation, in IL-2-dependent development of CD4 þ CD25 þ regulatory T cells and in IL-7/IL-15-dependent CD8 þ T cells homeostatic proliferation. Likewise, TgSTAT5A* mice display enhanced levels of bone marrow pro-B cells, hypersensitivity to weak proliferative signals in both the B-and T-cell lineages, expansion of CD8 þ memory T cells and increased development of CD4 þ CD25 þ regulatory T cells. However, these phenotypes were generally less pronounced in TgSTAT5A* mice as compared to previously described models, most probably because unlike these models in which STAT5 is overexpressed, STAT5A* is expressed at levels similar to endogenous STAT5 in the lymphoid lineage of TgSTAT5A* mice.
Activation of STAT5 as assessed by enhanced tyrosine phosphorylation and DNA-binding activity is frequently observed in human leukemia and lymphoma (for a review, see Bowman et al., 2000; Benekli et al., 2003) . Except for cases in which STAT5 activation can be linked to the expression of constitutively active protein tyrosine kinases including BCR-ABL or fusion oncoproteins involving TEL/ETV6 in CML and ALL, or FLT3-and c-KIT-activating mutations in AML (for review, see Sternberg and Gilliland, 2004) , the molecular events responsible for STAT5 activation in most cases remain ill-characterized. In our model, expression of the persistently activated STAT5A* mutant at levels similar to endogenous STAT5 is weakly oncogenic in vivo, resulting in B-cell leukemia only at low frequency and late onset. In line with its long latency, several lines of evidence indicate that leukemia emergence in TgSTA-T5A* mice requires the deregulation of additional molecular pathways. First, STAT5A*-induced leukemia is a clonal disease, indicating the selection of additional pro-oncogenic events during disease progression. Second, STAT5A*-induced B-cell lymphomagenesis is associated with upregulation of STAT5 tyrosine phosphorylation and DNA-binding activity, indicating that leukemia progression in TgSTAT5A* mice requires the deregulation of molecular pathways involved in STAT5 activation control. Finally, the STAT5A* transgene cooperates with the loss of function of the p53 tumor suppressor gene both to accelerate disease progression and to skew the large tumor spectrum normally observed in p53-deficient mice to strongly favor B-cell Figure 6 Analysis of the expression of negative regulators of the Janus kinase (JAK)/STAT pathway in transgenic STAT5A* (TgSTAT5A*) lymphoma/leukemia. (a) CD45 expression levels were analysed by cytometry on the B-cell population (CD19 þ ) from a non-transgenic LMC mouse (light gray line), from a nondiseased p53À/À mouse (dark gray line), from a non-diseased TgSTAT5A*/p53À/À mouse (black line) and from leukemic cells from three independent TgSTAT5A*/p53À/À mice (bold black lines). Dotted line: isotypic control. (b) Western blot performed with protein extracts from splenic cells from LMC and B-cell lymphoma/leukemia from p53À/À, TgSTAT5A*/p53 þ /À and TgSTAT5A*/p53À/À mice, using the indicated antibodies. Normalization was performed with an anti-ERK2 antibody.
STAT5 activation in B-cell neoplasia V Joliot et al lymphoma/leukemia. Recent studies have shown that the relative importance of cell cycle regulation, maintenance of genomic stability and apoptosis control in the tumor suppressive function of p53 appears to be distinct in the B-and T-cell lineages, with apoptosis playing a prevalent role in the B-cell lineage (Schmitt et al., 2002; Liu et al., 2004) . As constitutive STAT5 activation leads to the expansion of the pro-and pre-B-cell compartment, loss of function of p53 could contribute to leukemia development by activating survival pathways complementary to those controlled by STAT5. Alternatively, loss of p53 could increase the developmental window in the B-cell lineage in which activated STAT5 can manifest its pro-survival and proliferative capacities. Previous experiments have reported that wt p53 can counteract the transcriptional activation properties of STAT5 in transient reporter assays (Fritsche et al., 1998) . It is therefore possible that the loss of p53 function contributes to STAT5A*-induced leukemogenesis by releasing STAT5A* transcriptional activity from a direct negative regulatory input by wt p53. Additional studies are clearly required to distinguish among these or other possibilities.
Several experimental mouse models of STAT5-induced leukemia have been described that are distinct from the transgenic model described here. Expression of a transgene encoding wtSTAT5A or B in the lymphoid compartment results in high incidence T-cell leukemia (Kelly et al., 2003b) . Besides its specificity for the T-cell lineage, this model differs in two main aspects from TgSTAT5A* mice. First, unlike our mice that express STAT5A* at levels similar to endogenous STAT5, the wtSTAT5 transgenic mice express exogenous STAT5 at several fold higher levels than endogenous STAT5, with a clear correlation between the level of exogenous STAT5 expression and T-cell leukemia incidence (Kelly et al., 2003a) . Second, constitutive STAT5 tyrosine phosphorylation and DNA-binding activity was not detected in wtSTAT5-induced T-cell leukemias (Kelly et al., 2003b) , suggesting that the molecular mechanisms involved in STAT5-induced leukemogenesis in this model are distinct from those involved in both TgSTAT5A* mice and in human lymphomagenesis in which STAT5 activation occurs without change in STAT5 protein expression levels. The oncogenic activity of constitutively activated STAT5 has also been studied after retroviral transduction of mouse bone marrow cells followed by adoptive transfer of transduced cells into irradiated syngeneic hosts. Transduction of STAT5(H299R;S711F) induces a myeloproliferative disease that involves a non-cell autonomous component as evidenced by the expansion of non-transduced cells (Schwaller et al., 2000) . In contrast, in the same experimental setting, transduction of STAT5A* results in multilineage leukemia after short latency (Moriggl et al., 2005) , an observation suggesting that STAT5A* is a potent oncogene. These approaches differ in several respects from the TgSTAT5A* transgenic model described here. First, retroviral infection of bone marrow cells results in the expression of STAT5 mutants at levels several fold higher than endogenous STAT5 (Moriggl et al., 2005) , a fact that in itself can clearly contribute to STAT5 oncogenic activation (Kelly et al., 2003b) . Second, retroviral-mediated transduction results in the expression of STAT5 mutants in all bone marrow cells susceptible to retroviral infection, a setting which is unlikely to mimic STAT activation as it occurs during leukemia progression (Sommer et al., 2004) and which can result in non-cell autonomous effects (Schwaller et al., 2000) . Third, a fraction of leukemic cells in the transplantation model express cell surface markers of hematopoietic stem cell and multipotent progenitors, suggesting that these progenitors are potential target of STAT5A* transformation (Moriggl et al., 2005) , whereas the activity of the promoter used to express the STAT5A* transgene is largely confined to the lymphoid lineage. Hematopoietic stem cell targeting could be relevant to model STAT5 activation induced by fusion oncoproteins such as BCR-ABL (for a review, see Sternberg and Gilliland, 2004) . It is, however, unlikely to properly model other pathological situations in which STAT activation occurs only late, during disease progression (Sommer et al., 2004) .
Leukemia development in TgSTAT5A* mice is associated with further upregulation of STAT5 phosphorylation. This property appears to be dependent on JAK activity as shown by our inhibitor studies, suggesting the involvement of deregulated cytokine receptor signaling. The nature of the receptor(s) involved remains to be established, but available evidence shows that TgSTAT5A* leukemic cells express a functional IL-7R, suggesting their response to and possible dependence upon stroma-derived IL-7. Consistent with this, recent evidence has pointed to a critical role of STAT5 as modifier of disease onset in a mouse model of IL-7-induced lymphoma (Abraham et al., 2005) . A subset of TgSTAT5A* leukemic cells also express IL-7 RNA, suggesting in these cases further possibility for disease progression through the establishment of an autocrine loop. Proper testing of these hypotheses will require the analysis of compound mice in which conditional alleles for the genes encoding the IL-7Ra chain or IL-7 are combined with the STAT5A* transgene on a p53À/À background. Leukemia-associated hyperphosphorylation might also involve defects in negative regulation of JAK/STAT signaling (for a review, see Shuai and Liu, 2003) . Both PTP1B and SHPTP2 have been implicated as STAT5 phosphotyrosine phosphatases (Aoki and Matsuda, 2000; Chen et al., 2003) . We failed to detect decreased expression of these phosphatases between TgSTAT5A* leukemic cells and normal lymphoid cells, indicating that loss of expression of these phosphatases is not responsible for enhanced STAT5 tyrosine phosphorylation in TgSTA-T5A* leukemia. The genes encoding SHPTP1 and SOCS1, two negative regulators of the JAK/STAT pathway, are frequently methylated in human B-cell leukemia/lymphoma (Reddy et al., 2005) . However, we failed to detect any defect in SHPTP1 and SOCS1 expression in TgSTAT5A* leukemic cells, indicating that inactivation of these genes is unlikely to be instrumental in STAT5 hyperactivation in STAT5A* (Fleming et al., 2004) . It is therefore possible that the diminished expression of CD45 contributes to the enhanced activation of STAT5 observed in TgSTAT5A* leukemia.
Materials and methods
Transgene and mice
The cDNA encoding a C-terminal-flagged version of STAT-5A(S711F) (Onishi et al., 1998) was cloned in the EcoRV and HindIII sites of the pEmSRa (Bodrug et al., 1994) and transgenic mice generated as described previously (Carron et al., 2000) . Polymerase chain reaction (PCR) genotyping was performed using the following primers: 5 0 -CTTCAGT-GACTCGGAAAT-3 0 in the STAT5A sequence; and 5 0 -CCTACTTGTCATCGTCGCC-3 0 in the Flag sequence. Founders were backcrossed for eight generations onto wt C57BL/6 before analysis. F10 STAT5A(S711F) transgenic mice were also crossed with BALB/c p53À/À mice (Kuperwasser et al., 2000) . The p53 wt and null alleles were detected in a single PCR reaction, using the primers: 5 0 -CACATG TACTTGTAGTGGATGG-3 0 and 5 0 -ACAGCGTGGTGG-TACCTTAT-3 0 for the wt allele; and 5 0 -CTATCAGGACA-TAGCGTTGG-3 0 for the p53 null allele.
T-and B-cell separation and flow cytometric analysis Splenic T and B cells were separated using paramagnetic MicroBeads conjugated to anti-mouse CD4 and CD8 antibodies (MACS, Miltenyi Biotec, Paris, France), according to the manufacturer's instructions. Enriched T cells (85-90% Thy1.2 þ ) were obtained after elution from positive columns. The enriched B cells (90% B220 þ ) were obtained from the unselected cells in the above procedure after further depletion of T cells on negative selection columns.
Single-cell suspensions were prepared and stained as described previously (Carron et al., 2000) , using the following antibodies: anti-CD90.2 (Thy1.2)-FITC, anti-CD4-PE, antiCD8a-Cy-Chrome, anti-CD3e-FITC, anti-CD25-FITC, anti-CD44-APC, anti-B220/CD45R-CyChrome, anti-CD19-PE, anti-CD43-FITC, anti-IgM-FITC, anti-k chain-PE, anti-IgD-FITC, anti-pre-BCR-biotin, anti-Ly51/BP1-PE, anti-CD127-PE, anti-CD11b/Mac-1a chain-FITC, anti-Ly-6g/Gr-1-PE and anti-CD45-PE (Pharmingen, BD Biosciences, Le Pont-deClaix, France) and analysed by FACS (Becton-Dickinson FACSCalibur, CellQuestt software, BD Biosciences, Le Pontde-Claix, France).
Transplantation in nude mice and in vitro cell culture A total of 5 Â 10 6 leukemic cells were prepared in serum-free RPMI medium and injected subcutaneously in the back of 6-10 weeks old Swiss nu/nu mice (Charles Rivers, L'Arbrele, France). For inhibitor studies, cells were cultured in RPMI medium containing 5% fetal calf serum and 50 mM bmercaptoethanol. The PP1 inhibitor was obtained from Biosource and the pan-JAK inhibitor from Calbiochem (VWR, Fontenay-Sous-Bois, France). For apoptosis assays, cells were cultured (2 Â 10 6 cells/ml) with dexamethasone (5 mM; Sigma), SuperFas ligand (10 ng/ml; Alexis, Illkich, France), PMA (10 ng/ml; Sigma, St Quentin Fallavier, France), ionomycin (1 mg/ml; Sigma, St Quentin Fallavier, France), biotin-conjugated anti-CD3e (5 mg/ml; Pharmingen)-avidin (5 mg/ml). Apoptosis was quantified using the Annexin V-FITC kit (Beckman Coulter, Villepinte, France).
For T-cell proliferation assays, thymocytes or splenocytes were seeded in triplicate in 96-well plate pre-coated with an anti-CD3e antibody (1 mg/ml or 10 mg/ml) in the presence or absence of recombinant mouse IL-2 (R&D, Lille, France). Splenic B cells were stimulated by LPS (Sigma). After 48 hs, proliferation was quantified by 3 H-thymidine incorporation (0.1 mCi/well; Amersham, Orsay France). Lysates were spotted on glass fiber filters, washed and counted in OptiPhase Hisafe 2 (Perkin Elmer, Courteboeuf, France).
Western blot analysis and DNA-binding assays Whole-cell extracts were processed for Western blots as described previously (Lebigot et al., 2003) , using antibodies to: the Flag epitope (F3165; Sigma), STAT5A (71-2400; Zymed, Clinisciences, Montrouge, France), STAT5A þ B (SC-835; Santa-Cruz, Tebu, Paris, France), extracellular signalregulated protein kinase (ERK)2 (C-14; Santa Cruz), SOCS1 (SC7005; Santa Cruz), SOCS3 (SC7009; Santa Cruz), PTP1b (SC1718; Santa Cruz), SHPTP1 (SC287; Santa Cruz), SHPTP2 (SC280; Santa Cruz). Analyses with the anti-phospho-STAT5 antibody (UBI 05-495) were performed in 3% bovine serum albumin instead of non-fat dry milk. Immune complexes were revealed with horseradish peroxidase-conjugated anti-rabbit or anti-mouse Igs (Amersham) depending on the primary antibody used and enhanced chemoluminescence (ECL). Electrophoretic mobility shift assays were carried out as described previously (Carron et al., 2000) using duplex DNA probes for Sp1 5 0 -CGAGATTCGATCGGGGCGGGGCGAGC-3 0 (sense) and a STAT5-specific probe (b-caseinX2) containing tandemly repeated GAS motifs (underlined) to favor STAT5 tetramer formation 5 0 -AAGATTTCTAGGAATTCAATCTTCTAGG AATTCAATCC-3 0 (sense). Competitions were performed by including a 200-fold molar excess of either a conventional b-casein duplex oligonucleotide (MGF) 5 0 -AGAGATTTC TAGGAATTCAATCC-3 0 (sense), or the same oligonucleotide mutated in the core of the STAT5 DNA binding site: 5 0 -AGAGATTTAGTTTAATTCAATCC-3 0 (sense). Supershift assays were performed by using antibodies to STAT5 or NFAT4 (Santa Cruz).
Southern blot and semiquantitative reverse transcriptasepolymerase chain reaction analyses Genomic DNA 10 mg were digested with EcoRI and processed according to standard methods (Sambroock et al., 1989) . The probes used were a 900 bp HindIII-XbaI fragment encompassing the JH4 region of the IgH locus (kindly provided by M Goodhardt, Paris, France) and a 300 bp PstI-ClaI fragment encompassing the Jb2 region of the TCRb locus. RNA was purified using Trizol (Invitrogen, Cergy-Pontoise, France), using the supplier's protocols. Single-stranded cDNA were synthesized using the First Strand cDNA Synthesis kit (Amersham). The primers used for PCR were: 
